Company intelligence / Profile preview

Augere Medical

Ownership: Private
Development stage: Other

Overview

PolypAID™ has received CE-marking as a Class IIb medical device. The system uses artificial intelligence to assist clinicians during colonoscopies by augmenting colorectal cancer screening. The product has launched commercially in Europe but is not yet available elsewhere. Clinical results are not detailed publicly, but regulatory approval and commercial launch indicate successful validation.

Therapeutic areas: Gastroenterology
Modalities: DeviceArtificial intelligence-based diagnostic system
Industry: Digital Health Medical Devices

Partnerships

Simula Research Laboratory (R&D collaboration)

Beyond the preview

Go deeper on Augere Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Augere Medical.

Explore the full profile